# Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

> **NCT01011049** · PHASE2 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1250 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Influenza Virus Vaccine USP Trivalent Types A and B
- **BIOLOGICAL:** Influenza Virus Vaccine USP Trivalent Types A and B
- **BIOLOGICAL:** Influenza Virus Vaccine USP Trivalent Types A and B
- **BIOLOGICAL:** Influenza Virus Vaccine USP Trivalent Types A and B

## Key facts

- **NCT ID:** NCT01011049
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2010-05
- **Final completion:** 2010-10
- **Target enrollment:** 1250 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011049, "Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01011049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*